Suggested remit: To appraise the clinical and cost effectiveness of lenalidomide with rituximab within its marketing authorisation for untreated follicular lymphoma.
Company update
 
Status Suspended
Process STA pre-2018
ID number 1245

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
01 August 2018 Suspended, Company update
01 August 2018 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal (STA) of lenalidomide within its marketing authorisation for treating follicular, untreated lymphoma. Following a recent update from the company, NICE has decided to suspend this appraisal on its work programme. As the appraisal has been referred, NICE will continue to monitor any developments and will provide a further update in due course.
08 June 2018 - 06 July 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
27 June 2018 In progress, DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance